TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Benzer Materyaller

• Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
  Yazar:: Jørgensen, Charlotte LT, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?
  Yazar:: Munro, Alison F, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Danish Breast Cancer Cooperative Group
  Yazar:: Christiansen, Peer, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  Yazar:: Iben Kümler, ve diğerleri
  Baskı/Yayın Bilgisi: (2019-06-01)
• Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
  Yazar:: Kümler, Iben, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)